FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE QOLIANA® (brimonidine tartrate ophthalmic solution), 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. 2 DOSAGE AND ADMINISTRATION

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information --------------WARNINGS AND PRECAUTIONS-----------­ needed to use QOLIANA® (brimonidine tartrate • Potentiation of vascular insufficiency (5.1). ophthalmic solution), 0.15% safely and effectively. See full prescribing information for QOLIANA® --------------------ADVERSE REACTIONS-------------------(brimonidine tartrate ophthalmic solution), 0.15%. Most common adverse reactions are allergic conjunctivitis, conjunctival hyperemia, and eye pruritis (6.1). QOLIANA® (brimonidine tartrate ophthalmic solution), 0.15% To report SUSPECTED ADVERSE REACTIONS, Initial U.S. Approval: 1996 contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. -----------------INDICATIONS AND USAGE----------------­ QOLIANA® (brimonidine tartrate ophthalmic solution), --------------------DRUG INTERACTIONS-------------------• Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade (7.1). • Use with CNS depressants may result in an additive or potentiating effect (7.2). • Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine (7.3). • Monoamine oxidase inhibitors may result in increased hypotension (7.4). 0.15% is an alpha-2 adrenergic receptor agonist indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension (1).